

CITATION REPORT

List of articles citing

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

DOI: 10.1073/pnas.0830997100

Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4712-7.

Source: <https://exaly.com/paper-pdf/35680157/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
909	Sun Tzu and the Art of Business Sun Tzu and the Art of Business By McNeilly Mark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
908	Cellular immunity for cancer chemoimmunotherapy--an overview. 2003 , 52, 661-2		5
907	Modulation of costimulation to enhance tumor immunity. 2003 , 52, 663-9		17
906	Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. 2003 , 15, 725-30		44
905	Don't forget the handbrake. 2003 , 3, 316-316		
904	Antibodies as therapeutic agents: vive la renaissance!. 2003 , 3, 1133-52		60
903	Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. 2003 , 21, 3343-50		253
902	Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. 2003 , 171, 6251-9		114
901	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8372-7	11.5	1325
900	. 2004 ,		6
899	Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. 2004 , 51, 271-93		8
898	Novel therapies for recurrent ovarian cancer management. 2004 , 4, 437-48		12
897	B7-H1-targeted immunotherapy for head and neck cancer. 2004 , 4, 1577-83		3
896	Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. 2004 , 172, 1449-54		39
895	CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. 2004 , 172, 2778-84		208
894	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 17174-9	11.5	657
893	Altering immune tolerance therapeutically: the power of negative thinking. 2004 , 75, 586-99		16

892	Immunotherapy: bewitched, bothered, and bewildered no more. 2004 , 305, 197-200	110
891	A simple method to cure established tumors by inflammatory killing of normal cells. 2004 , 22, 1125-32	97
890	Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. 2004 , 22, 1546-53	216
889	An innately interesting decade of research in immunology. 2004 , 10, 1307-20	111
888	Cancer vaccines: pessimism in check. 2004 , 10, 1278-9; author reply 1279-80	40
887	Cancer vaccines: pessimism in check. 2004 , 10, 1279; author reply 1279-80	16
886	Reply to "Cancer vaccines: pessimism in check". 2004 , 10, 1279-1280	15
885	Cytokines in cancer pathogenesis and cancer therapy. 2004 , 4, 11-22	1018
884	The promise of cancer vaccines. 2004 , 4, 401-11	221
883	Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. 2004 , 4, 336-47	982
882	Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. 2004 , 25, 400-7	5
881	Cancer immunotherapy: a treatment for the masses. 2004 , 305, 200-5	492
880	Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. 2004 , 53, 1018-26	37
879	Costimulation-based immunotherapy for head and neck cancer. 2004 , 5, 27-33	11
878	Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. 2004 , 112, 509-18	30
877	Current developments of immunotherapy in the clinic. 2004 , 16, 130-6	65
876	Using antibodies in tumour immunotherapy. 2004 , 4, 1265-84	7
875	Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. 2004 , 6, 208-14	18

874	Colorectal cancer vaccines: principles, results, and perspectives. 2004 , 127, 1821-37	26
873	Immune mechanisms in neoplasia. 2004 , 1, 375-381	
872	Immunotherapy for melanoma. 2004 , 22, 251-65	44
871	Cancer vaccine development: on the way to break immune tolerance to malignant cells. 2004 , 299, 267-78	29
870	CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. 2004 , 22, 1700-8	104
869	Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection. 2005 , 001-018	
868	Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. 2004 , 27, 354-67	100
867	Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. 2004 , 27, 478-9	130
866	Manipulating dendritic cell biology for the active immunotherapy of cancer. 2004 , 104, 2235-46	278
865	Immunological Safety of Vaccines: Facts, Hypotheses and Allegations. 2004 , 595-611	3
864	Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. 2004 , 20, 13-24	18
863	Rodent models of brain metastasis in melanoma. 2005 , 15, 325-56	35
862	Vaccine strategies to treat lymphoproliferative disorders. 2005 , 37, 534-50	10
861	Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. 2005 , 28, 593-8	285
860	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. 2005 , 105, 13-21	248
859	Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. 2005 , 105, 1114-20	24
858	Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. 2005 , 105, 4399-406	46
857	Erratum for vol. 104, p. 3422. 2005 , 105, 21-21	1

856	Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. 2005 , 106, 3127-33	80
855	Combining radiotherapy and immunotherapy: a revived partnership. 2005 , 63, 655-66	265
854	Dendritic-cell-based therapeutic vaccination against cancer. 2005 , 17, 163-9	165
853	Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. 2005 , 12, 957-9	2
852	Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. 2005 , 65, 591-604	36
851	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. 2005 , 130, 809-24	37
850	Human antibodies from transgenic animals. 2005 , 23, 1117-25	325
849	Immunosuppressive networks in the tumour environment and their therapeutic relevance. 2005 , 5, 263-74	1627
848	Development and immunophenotyping of squamous cell carcinoma xenografts: tools for translational immunology. 2005 , 115, 1154-62	3
847	Regulatory T cells in ovarian cancer: biology and therapeutic potential. 2005 , 54, 369-77	180
846	Molecular regulation of Th2 immunity by dendritic cells. 2005 , 106, 75-96	17
845	CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. 2005 , 54, 944-52	17
844	Breaking tolerance in cancer immunotherapy: time to ACT. 2005 , 17, 187-94	53
843	Dendritic cells in melanoma immunotherapy. 2005 , 6, 175-84	3
842	Immunotherapy for melanoma: the good, the bad, and the future. 2005 , 7, 383-92	8
841	Cancer vaccines: the challenge of developing an ideal tumor killing system. 2005 , 10, 2285-305	13
840	Novel Therapies for Renal Cell Cancer. 2005 , 204-217	
839	Immune Modulations. 2005 , 475-490	

838	Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. 2005 , 5, 7-22	11
837	Prostate cancer immunology: biology, therapeutics, and challenges. 2005 , 23, 8262-9	35
836	Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. 2005 , 11, 2947-53	630
835	CTLA-4 blockade: autoimmunity as treatment. 2005 , 23, 8926-8	28
834	Antisense therapy for restenosis following percutaneous coronary intervention. 2005 , 5, 79-89	15
833	Dendritic cells: tools and targets for antitumor vaccination. 2005 , 4, 699-710	38
832	Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. 2005 , 23, 741-50	395
831	Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. 2005 , 23, 999-1010	154
830	Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. 2005 , 23, 8968-77	492
829	CTLA-4 blockade: unveiling immune regulation. 2005 , 23, 662-4	40
828	T regulatory cell depletion can boost DC-based vaccines. 2005 , 4, 628-630	4
827	Cutaneous melanoma. 2005 , 365, 687-701	463
826	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. 2005 , 4, 1645-52	26
825	Immunotherapy for gynaecological malignancies. 2005 , 5, 1193-210	30
824	Dendritic cell fusion vaccines for cancer immunotherapy. 2005 , 5, 703-15	35
823	Therapeutic vaccines for melanoma: current status. 2005 , 19, 247-60	28
822	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. 2005 , 5, 463-76	54
821	Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. 2005 , 65, 2009-17	72

820	TGF-beta inhibitors for the treatment of cancer. 2005 , 14, 629-43	71
819	Towards a therapeutic breast cancer vaccine: the next steps. 2005 , 4, 831-41	3
818	Novel therapies in lung cancer. 2005 , 19, 343-67, vii	4
817	Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. 2006 , 90, 215-41	45
816	Checkpoint blockade in cancer immunotherapy. 2006 , 90, 297-339	414
815	Can we use monoclonal antibodies to help T cells fight tumors?. 2006 , 8, 1-2	
814	Tumor Immunology and Immunotherapy. 2006 , 254-268	
813	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. 2006 , 55, 1432-42	73
812	DNA vaccines against cancer. 2006 , 20, 613-36	16
811	CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. 2006 , 8, 3-12	39
810	Immunotherapy of melanoma. 2006 , 20, 751-66	14
809	Therapeutic lymphoma vaccines: importance of T-cell immunity. 2006 , 5, 381-94	16
808	B7-H3 and B7-H4 expression in non-small-cell lung cancer. 2006 , 53, 143-51	249
807	Waking up T cells to counteract chronic infections. 2006 , 27, 205-7	4
806	Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. 2006 , 24, 442-7	37
805	Costimulatory molecules as adjuvants for immunotherapy. 2006 , 11, 788-803	42
804	Tumor antigen targets and tumor immunotherapy. 2006 , 11, 337-43	10
803	Vaccination to treat noninfectious diseases: surveying the opportunities. 2006 , 289-317	

802	Therapeutic potential of immunostimulatory monoclonal antibodies. 2006 , 111, 93-106	13
801	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity. 2006 , 331-353	
800	Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. 2006 , 142, 166-72	85
799	Dendritic cell immunotherapy for melanoma. 2006 , 1, 87-102	2
798	The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. 2006 , 16, 379-83	16
797	The Tumor Microenvironment. 2006 , 285-301	
796	Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. 2006 , 84, 303-17	90
795	Circulating levels and clinical significance of soluble CD86 in myeloma patients. 2006 , 133, 165-72	11
794	PD-1 blockade: rescue from a near-death experience. 2006 , 7, 227-8	22
793	Regulatory T cells, tumour immunity and immunotherapy. 2006 , 6, 295-307	1581
792	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. 2006 , 18, 206-13	367
791	Effective cancer therapy through immunomodulation. 2006 , 57, 65-81	68
790	Immuntherapie in der gynkologischen Onkologie. 2006 , 39, 158-164	
789	Adoptive T cell therapy of solid cancers. 2006 , 55, 96-103	27
788	Therapeutic cancer vaccines. 2006 , 18, 201-5	113
787	Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes. 2006 , 121, 215-26	19
786	CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. 2006 , 16, 150-9	33
785	Combinatorial cancer immunotherapy. 2006 , 90, 341-68	38

784	Antibodies and their fragments as anti-cancer agents. 2006 , 12, 363-78	31
783	Mechanisms of CTLA-4-Ig in tolerance induction. 2006 , 12, 149-60	58
782	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. 2006 , 24, 2283-9	691
781	Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. 2006 , 12, 4794-803	90
780	Modulation of immune response by B7 family molecules in tumor microenvironments. 2006 , 35, 395-418	11
779	Induction of tumor immunity following allogeneic stem cell transplantation. 2006 , 90, 133-73	62
778	Development of antibodies and chimeric molecules for cancer immunotherapy. 2006 , 90, 83-131	36
777	Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. 2006 , 177, 4168-77	38
776	Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. 2006 , 66, 2442-50	110
775	Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9190-5	11.5 140
774	Roadmap to a better therapeutic tumor vaccine. 2006 , 25, 415-43	28
773	GM-CSF gene-modified cancer cell immunotherapies: of mice and men. 2006 , 25, 321-52	80
772	Dendritic cell-based tumor vaccines and antigen presentation attenuators. 2006 , 13, 850-8	25
771	Malignant melanoma: genetics and therapeutics in the genomic era. 2006 , 20, 2149-82	379
770	Vaccination: role in metastatic melanoma. 2006 , 6, 1305-18	21
769	Interferon beta adenoviral gene therapy in a patient with ovarian cancer. 2006 , 3, 633-9	25
768	Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. 2006 , 12, 3394-401	102
767	Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria. 2006 , 74, 2277-85	21

766	Cutaneous melanoma: an update on therapies. 2006 , 1, 43-49	
765	Clinical results of vaccine therapy for cancer: learning from history for improving the future. 2006 , 95, 147-202	38
764	A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. 2007 , 13, 1810-5	338
763	Role of monoclonal antibodies in tumor-specific immunity. 2007 , 7, 331-43	8
762	Toxicity as a result of immunostimulation by biologics. 2007 , 3, 209-34	35
761	The expansion and maintenance of antigen-selected CD8(+) T cell clones. 2007 , 96, 103-39	26
760	Ovarian cancer vaccine trials and tribulations. 2007 , 7, 103-12	
759	Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. 2007 , 12, 864-72	240
758	Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. 2007 , 67, 4783-9	74
757	Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. 2007 , 12, 873-83	132
756	Triggering tumor immunity through angiogenesis targeting. 2007 , 13, 3762-4	7
755	Anti-CTL-associated antigen 4: are regulatory T cells a target?. 2007 , 13, 785-8	23
754	Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. 2007 , 67, 11970-9	78
753	BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. 2007 , 7, 113-22	20
752	A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. 2007 , 13, 958-64	143
751	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. 2007 , 13, 2158-67	235
750	CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. 2007 , 101, 248-57	57
749	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19458-63	11.5 283

748	Stat3 as a potential target for cancer immunotherapy. 2007 , 30, 131-9	72
747	Current topics in melanoma. 2007 , 19, 116-20	19
746	Exploiting regulatory T-cell populations for the immunotherapy of cancer. 2007 , 30, 591-5	15
745	The new B7s: playing a pivotal role in tumor immunity. 2007 , 30, 251-60	157
744	Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. 2007 , 30, 825-30	564
743	Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes. 2007 , 30, 350-8	6
742	Prostate cancer immunotherapy. 2007 , 17, 175-81	20
741	Combining Vaccines with Conventional Therapies for Cancer. 2007 , 2, 33-39	15
740	Anti-CTLA4 Antibody Clinical Trials in Melanoma. 2007 , 2, 133-139	36
739	Vaccine therapy for melanoma: current status and future directions. 2007 , 25 Suppl 2, B4-16	65
738	Enhancing cancer vaccines with immunomodulators. 2007 , 25 Suppl 2, B72-88	43
737	Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. 2007 , 143, 958-969	15
736	Current immunotherapeutic strategies in pancreatic cancer. 2007 , 16, 919-43, xi	7
735	Immunosuppressive strategies that are mediated by tumor cells. 2007 , 25, 267-96	1260
734	Emerging concepts in monoclonal antibody therapy. 2007 , 5, 442-443	
733	General Principles of Tumor Immunotherapy. 2007 ,	2
732	Cytotoxic T-lymphocyte-associated antigen-4. 2007 , 13, 5238-42	60
731	The B7 family and cancer therapy: costimulation and coinhibition. 2007 , 13, 5271-9	277

730	Cytokine therapy for cancer. 2007 , 16, 793-818, viii	24
729	Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. 2007 , 82, 490-513	105
728	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. 2007 , 257-275	
727	Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. 2007 , 9, 1-20	41
726	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. 2007 , 12, 4568-94	9
725	Immunotherapy and Cancer Therapeutics: Why Partner?. 2007 , 207-233	4
724	Therapeutic vaccine for lymphoma. 2007 , 48, 1-10	5
723	State of the Science. 2007 , 22, 18-21	
722	Jump-Starting Tumor Immunity with Breast Cancer Therapeutics. 2007 , 169-187	
721	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. 2007 , 110, 2614-27	231
720	Novel treatment strategies for malignant melanoma: a new beginning?. 2007 , 62, 16-22	23
719	Learning the drug target-likeness of a protein. 2007 , 7, 4255-63	23
718	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. 2007 , 8, 1246-54	411
717	Immunostimulatory monoclonal antibodies for cancer therapy. 2007 , 7, 95-106	487
716	Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. 2007 , 7, 701-6	60
715	CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. 2007 , 21, 1451-9	42
714	Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. 2008 , 263, 61-9	55
713	Immunodeficiency and immunotherapy in multiple myeloma. 2007 , 138, 563-79	250

712	Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. 2007 , 5, 347-50	10
711	Challenges and prospects of immunotherapy as cancer treatment. 2007 , 1776, 108-23	27
710	Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. 2007 , 125, 76-87	52
709	CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. 2007 , 35, 920-30	9
708	Inhibitory costimulation and anti-tumor immunity. 2007 , 17, 288-98	23
707	Immunotherapeutic strategies for high-risk bladder cancer. 2007 , 34, 165-72	27
706	Melanoma vaccines. 2007 , 34, 516-23	19
705	The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. 2007 , 56, 1471-84	32
704	Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. 2007 , 56, 2003-16	44
703	Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. 2007 , 56, 1687-700	155
702	Tumor resistance to CD8+ T cell-based therapeutic vaccination. 2007 , 55, 205-17	7
701	Towards progress on DNA vaccines for cancer. 2007 , 64, 2391-403	31
700	First world meeting of interdisciplinary melanoma/skin cancer centers. 2007 , 299, 277-304	
699	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. 2008 , 57, 1263-70	47
698	[Immunomodulatory antibodies in the treatment of skin cancer]. 2008 , 59, 806-13	2
697	Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. 2008 , 28, 413-44	29
696	Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. 2008 , 38, 2499-511	46
695	Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?. 2008 , 30, 251-61	42

694	CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. 2008 , 15, 3014-21	45
693	Human monoclonal antibodies from transgenic mice. 2008 , 69-97	56
692	Cancer immunology. 2008 , 358, 2704-15	690
691	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. 2008 , 224, 141-65	182
690	Immunotherapy for advanced melanoma. 2008 , 128, 2596-2605	58
689	TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. 2008 , 27, 168-80	138
688	Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. 2008 , 222, 287-98	70
687	CTLA-4: a key regulatory point in the control of autoimmune disease. 2008 , 223, 143-55	139
686	Invariant natural killer T cells and immunotherapy of cancer. 2008 , 129, 182-94	29
685	Locoregional treatment of malignant hepatic tumors with biologic response modifiers. 2008 , 17, 935-55, xii	2
684	Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. 2008 , 6, 22	66
683	Dendritic cells in cancer immunotherapy. 2008 , 99, 363-407	55
682	Targeted therapeutic strategies in malignant melanoma. 2008 , 5, e63-e68	4
681	Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. 2008 , 26, 5275-83	261
680	Cancer vaccines: on the threshold of success. 2008 , 13, 295-308	47
679	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 20410-5	11.5 291
678	Targeted Cancer Therapy. 2008 ,	6
677	The complex role of B7 molecules in tumor immunology. 2008 , 14, 550-9	71

676	Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody. 2008 , 59, S60-1	4
675	Cutaneous myxoid fibroblastoma. 2008 , 59, S61-4	4
674	"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. 2008 , 20, 296-300	24
673	Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. 2008 , 5, 367-374	7
672	Metastatic melanoma: an AJCC review. 2008 , 5, 441-445	4
671	High levels of granzyme B expression in invasive cervical carcinoma correlates to poor response to treatment. 2008 , 26, 499-503	7
670	Adverse consequences of immunostimulation. 2008 , 5, 33-41	29
669	Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. 2008 , 14, 4898-907	49
668	Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). 2008 , 13 Suppl 4, 16-25	71
667	Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. 2008 , 68, 7025-34	130
666	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. 2008 , 14, 5242-9	91
665	An effective vaccine strategy protective against antigenically distinct tumor variants. 2008 , 68, 2471-8	10
664	Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?. 2008 , 8, 465-74	3
663	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. 2008 , 26, 955-62	210
662	CTLA-4 blockade increases IFN γ -producing CD4+ICOS $^+$ cells to shift the ratio of effector to regulatory T cells in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14987-92	11.5 407
661	Outlining the Gap Between Preclinical Models and Clinical Situation. 2008 , 31-54	
660	Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. 2008 , 180, 699-705	69
659	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3005-10	11.5 533

658	Principles of Molecular Oncology. 2008 ,	1
657	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. 2008 , 205, 2125-38	167
656	The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. 2008 , 13 Suppl 4, 2-9	178
655	Melanoma. 2008 ,	1
654	Phase I/II study of ipilimumab for patients with metastatic melanoma. 2008 , 26, 5950-6	385
653	Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. 2008 , 14, 2740-8	85
652	CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. 2008 , 5, 557-61	143
651	Advances in tumour immunotherapy. 2008 , 101, 675-83	22
650	Immunotherapy opportunities in ovarian cancer. 2008 , 8, 243-57	52
649	Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. 2008 , 111, 1404-12	27
648	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. 2008 , 112, 1175-83	196
647	The use of the inhibitory receptors for modulating the immune responses. 2008 , 14, 2643-50	17
646	CTLA-4: negative regulator of the immune response and a target for cancer therapy. 2008 , 31, 431-9	24
645	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. 2008 , 3, 362-7	39
644	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. 2008 , 31, 586-90	85
643	Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. 2008 , 32, 1130-7	118
642	Pitfalls or promise in prostate cancer immunotherapy-which is winning?. 2008 , 14, 26-34	8
641	What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. 2009 , 14, 848-61	83

640	T cell receptor gene therapy for cancer. 2009 , 20, 1240-8		75
639	Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). 2009 , 4, 199-210		10
638	Anti-CTLA-4 therapy results in higher CD4+ICOS ^{hi} T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2729-34	11.5	157
637	T-regulatory cell modulation: the future of cancer immunotherapy?. 2009 , 100, 1697-703		77
636	Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. 2009 , 15, 2507-13		79
635	Inhibitors of B7-CD28 costimulation in urologic malignancies. 2009 , 1, 129-39		9
634	Molecular-targeted therapy in malignant melanoma. 2009 , 9, 567-81		11
633	Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. 2009 , 48, 391-400		30
632	Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. 2009 , 15, 390-9		103
631	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. 2009 , 206, 1717-25		677
630	Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. 2009 , 69, 609-15		211
629	Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. 2009 , 133, 333-52		33
628	Abatacept therapy and safety management. 2009 , 76 Suppl 1, S3-S55		27
627	CD152 (CTLA-4) regulates effector functions of CD8 ⁺ T lymphocytes by repressing Eomesodermin. 2009 , 39, 883-93		25
626	Making and circumventing tolerance to cancer. 2009 , 39, 2345-53		12
625	Immunomodulation in the treatment of haematological malignancies. 2009 , 9, 81-92		6
624	Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. 2009 , 54, 2538-40		101
623	Ipilimumab: controversies in its development, utility and autoimmune adverse events. 2009 , 58, 823-30		205

622	T regulatory cells and their counterparts: masters of immune regulation. 2009 , 39, 626-39	111
621	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. 2009 , 157, 9-19	111
620	CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. 2009 , 6, 123-7	22
619	Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 2009 , 16, 900-11	44
618	Costimulatory and coinhibitory receptors in anti-tumor immunity. 2009 , 229, 126-44	202
617	T cell-mediated immunoregulation in the gastrointestinal tract. 2009 , 64, 505-19	64
616	Targets of protective tumor immunity. 2009 , 1174, 74-80	26
615	PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. 2009 , 182, 5891-7	189
614	Cancer immunotherapy. 2009 , 46, 167-89	61
613	Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. 2009 , 7, 45	31
612	Immune therapy for cancer. 2009 , 27, 83-117	476
611	2A to the fore - research, technology and applications. 2010 , 26, 223-60	35
610	Tumor vaccines for breast cancer. 2009 , 27, 361-8	33
609	Human Antibodies from Transgenic Mice. 115-150	
608	Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). 2009 , 32, 322-4	71
607	Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade. 2009 , 4, 681-698	18
606	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. 2009 , 113, 1681-8	27
605	Chemokine receptors as targets for cancer therapy. 2009 , 15, 742-57	65

604	Suppressive influences in the immune response to cancer. 2009 , 32, 1-11	62
603	Peptide-based anticancer vaccines: recent advances and future perspectives. 2009 , 16, 4779-96	36
602	Immune regulatory antibodies: are they the next advance?. 2010 , 16, 311-7	24
601	B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. 2010 , 252, 1044-51	96
600	Interface of signal transduction inhibition and immunotherapy in melanoma. 2010 , 16, 360-6	8
599	Anti-HER2 vaccines: new prospects for breast cancer therapy. 2010 , 59, 1295-312	97
598	Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. 2010 , 16, 547-51	22
597	Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. 2010 , 13, 29-38	218
596	Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. 2010 , 37, 485-98	130
595	Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. 2010 , 37, 533-46	183
594	Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. 2010 , 46, 543-8	24
593	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. 2010 , 116, 1767-75	364
592	Dendritic cells in cancer immunotherapy. 2010 , 40, 2123-30	89
591	Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. 2010 , 102, 748-52	36
590	The biologic importance of tumor-infiltrating lymphocytes. 2010 , 37 Suppl 1, 48-53	31
589	Immunotherapy of melanoma. 2010 , 6 Suppl 1, S2-8	8
588	Overcoming immunological tolerance to melanoma: Targeting CTLA-4. 2010 , 6 Suppl 1, S16-23	21
587	6.6 Vakzinierung. 2010 ,	

586	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. 2010 , 16, 2861-71	347
585	Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. 2010 , 2010, 139304	4
584	RNA as performance-enhancers for dendritic cells. 2010 , 10, 563-74	16
583	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. 2010 , 21, 1712-1717	397
582	Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. 2010 , 25, 601-13	104
581	Mechanisms of T-cell inhibition: implications for cancer immunotherapy. 2010 , 9, 89-105	22
580	Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. 2010 , 29, 461-84	5
579	Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. 2010 , 16, 255-67	25
578	Active immunotherapy induces antibody responses that target tumor angiogenesis. 2010 , 70, 10150-60	60
577	Antibodies to watch in 2010. 2010 , 2, 84-100	75
576	B7-h3 and its role in antitumor immunity. 2010 , 2010, 683875	85
575	Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. 2010 , 28, 1196-202	16
574	Antibodies in cancer immunotherapy. 2010 , 6, 291-305	2
573	Enhanced T cell receptor gene therapy for cancer. 2010 , 10, 749-62	11
572	Modulation of CTLA-4 and GITR for cancer immunotherapy. 2011 , 344, 211-44	21
571	The role of tregs in glioma-mediated immunosuppression: potential target for intervention. 2010 , 21, 125-37	45
570	Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. 2010 , 10, 1697-701	24
569	Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. 2010 , 139, 58-72.e4	211

568	+49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. 2010 , 71, 83-7	50
567	The inhibition of the T-cell immunoglobulin and mucin domain 3 (Tim3) pathway enhances the efficacy of tumor vaccine. 2010 , 402, 88-93	15
566	Whole tumor antigen vaccines. 2010 , 22, 132-43	147
565	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. 2010 , 11, 155-64	910
564	Melanoma vaccines: developments over the past 10 years. 2011 , 10, 853-73	26
563	The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. 2012 , 351, 181-220	12
562	Specific immunotherapy and turning off the T cell: how does it work?. 2011 , 107, 381-92	23
561	Cancer Immunology and Immunotherapy. 2011 ,	1
560	Cancer immunotherapy. 2011 , 26, 1-64	102
559	Emerging Therapeutic Targets in Ovarian Cancer. 2011 ,	1
558	Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. 2011 , 30, 150-82	79
557	Autoimmunity associated with immunotherapy of cancer. 2011 , 118, 499-509	128
556	B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. 2011 , 102, 1019-24	65
555	Roles of the immune system in skin cancer. 2011 , 165, 953-65	114
554	CTLA-4 to overcome immunological tolerance to melanoma. 2011 , 7, 14-19	
553	Update on monoclonal antibodies for the treatment of cancer. 2011 , 7, 20-25	
552	Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. 2011 , 9, 277-86	61
551	Behandlung und Nebenwirkungsmanagement des metastasierten Melanoms mit CTLA-4-Antikörpern. 2011 , 9, 277-286	26

550	Timeline: a decade of advances in immunotherapy. 2011 , 17, 296	3
549	Rethinking ovarian cancer: recommendations for improving outcomes. 2011 , 11, 719-25	893
548	Vaccine-based clinical trials in ovarian cancer. 2011 , 10, 775-84	12
547	A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. 2011 , 29, 489-98	230
546	Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. 2011 , 30, 141-51	41
545	CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. 2011 , 60, 1137-46	74
544	Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 2011 , 41, 3553-63	58
543	Anti-angiogenesis immunotherapy. 2011 , 7, 976-81	16
542	Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. 2011 , 15, 503-6	32
541	Immunotherapy for ovarian cancer: what's next?. 2011 , 29, 925-33	95
540	Targeting the tumor microenvironment by immunotherapy: part 2. 2011 , 3, 1385-408	5
539	CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. 2011 , 17, 4101-9	113
538	CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis. 2011 , 82, 439-44	24
537	Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. 2011 , 12, 367-77	17
536	Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. 2011 , 17, 896-906	158
535	Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. 2011 , 3, 2904-54	10
534	The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. 2011 , 2011, 182413	7
533	Atypical clinical response patterns to ipilimumab. 2011 , 15, 393-403	14

532	Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. 2012 , 2012, 196063	32
531	Pulmonary sarcoid-like granulomatosis induced by ipilimumab. 2012 , 30, e156-9	146
530	Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. 2012 , 3, 103	5
529	Immunotherapies: the blockade of inhibitory signals. 2012 , 8, 1420-30	23
528	Immunotherapy in ovarian cancer. 2012 , 8, 1179-91	36
527	Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism and susceptibility to pancreatic cancer. 2012 , 31, 683-7	17
526	Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. 2012 , 30, e356-7	34
525	Ipilimumab pharmacotherapy in patients with metastatic melanoma. 2012 , 6, 275-86	5
524	CTLA-4-Tg/CD-28-KO Mice Exhibit Reduced T Cell Proliferation in vivo Compared to CD-28-KO Mice in a Graft-versus-host Disease Model. 2012 , 16, 349-53	4
523	Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. 2012 , 2012, 485781	52
522	Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II. 2012 , 11, 351-63	13
521	Revisiting the role of T cells in tumor regression. 2012 , 1, 346-350	12
520	Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. 2012 , 4, 625-630	21
519	Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. 2012 , 12, 61-6	5
518	Immunology beats cancer: a blueprint for successful translation. 2012 , 13, 1129-32	130
517	Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. 2012 , 65, 9-22	89
516	Immunotherapy of Cancer. 2012 , 391-414	12
515	The expression, function, and clinical relevance of B7 family members in cancer. 2012 , 61, 1327-41	62

514	Therapeutic cancer vaccines: current status and moving forward. 2012 , 104, 599-613	207
513	Immunotherapy earns its spot in the ranks of cancer therapy. 2012 , 209, 201-9	108
512	Management of immune-related adverse events and kinetics of response with ipilimumab. 2012 , 30, 2691-7	1057
511	Tumor-associated antigen expressing <i>Listeria monocytogenes</i> induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. 2012 , 19 Suppl 3, S597-607	22
510	Co-Administration of Co-Stimulatory Moieties. 2012 , 375-392	
509	Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. 2012 , 42, 2060-72	95
508	Ipilimumab in the treatment of melanoma. 2012 , 12, 773-82	17
507	Leukemia and Related Disorders. 2012 ,	3
506	Innate Immune Regulation and Cancer Immunotherapy. 2012 ,	3
505	Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. 2012 , 174-7	40
504	Ipilimumab: report and comment about the MDX010-020 clinical trial. 2012 , 7, 507-512	
503	The blockade of immune checkpoints in cancer immunotherapy. 2012 , 12, 252-64	8091
502	State of the science: an update on renal cell carcinoma. 2012 , 10, 859-80	121
501	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. 2012 , 61, 1137-47	73
500	Whole cell vaccines--past progress and future strategies. 2012 , 39, 276-86	89
499	Translatibility scoring in drug development: eight case studies. 2012 , 10, 39	30
498	Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. 2012 , 61, 157-168	33
497	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. 2013 , 11, 149	50

496	Therapeutic cancer vaccines: past, present, and future. 2013 , 119, 421-75	361
495	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. 2013 , 11, 4	35
494	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. 2013 , 19, 5300-9	485
493	Antibodies to Stimulate Host Immunity. 2013 , 287-307	2
492	Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. 2013 , 17, 458-63	14
491	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. 2013 , 19, 462-8	407
490	Immune Co-signaling to Treat Cancer. 2013 , 211-280	1
489	Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. 2013 , 18, 717-25	66
488	Advances in targeting cell surface signalling molecules for immune modulation. 2013 , 12, 130-46	192
487	Endocrine side effects induced by immune checkpoint inhibitors. 2013 , 98, 1361-75	299
486	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. 2013 , 13, 847-61	96
485	Developing melanoma therapeutics: overview and update. 2013 , 5, 257-71	13
484	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. 2013 , 621-642	
483	T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. 2013 , 62, 245-56	72
482	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. 2013 , 76, 233-47	31
481	Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. 2013 , 40, 347-60	13
480	Therapeutic vaccines for ovarian cancer. 2013 , 130, 667-73	12
479	The Tumor Immunoenvironment. 2013 ,	3

478	T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. 2013 , 26, 441-56	11
477	Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. 2013 , 1, 229-34	149
476	[Immune-checkpoints: the new anti-cancer immunotherapies]. 2013 , 100, 601-10	7
475	Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. 2013 , 19, 5381-9	133
474	Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. 2013 , 190, 6250-8	45
473	Monoclonal antibodies therapies for ovarian cancer. 2013 , 13, 739-64	19
472	Expression of cytotoxic T-lymphocyte antigen 4 on CD4+ and CD8+ T cells is increased in acute lung injury. 2013 , 32, 722-6	3
471	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. 2013 , 210, 1389-402	452
470	Use of ipilimumab in the treatment of melanoma. 2013 , 5, 21-7	13
469	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. 2013 , 5, 13-9	6
468	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. 2013 , 5, 55-61	13
467	The nature of activatory and tolerogenic dendritic cell-derived signal II. 2013 , 4, 53	71
466	Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. 2013 , 1, 2-8	12
465	Pilomatricoma of the pinna. 2013 , 92, 34-40	3
464	Gene Therapy for Melanoma: Progress and Perspectives. 2013 ,	1
463	Primary mucosal melanoma arising from the eustachian tube with CTLA-4, IL-17A, IL-17C, and IL-17E upregulation. 2013 , 92, 36-40	12
462	Emerging options for the treatment of melanoma - focus on ipilimumab. 2014 , 3, 67-78	2
461	. 2014 ,	0

460	Opening the door to innovation. 2014 , 6, 812-9	12
459	Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma. 2014 , 18, 574-9	7
458	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. 2014 , 2, 40	41
457	Ovarian cancer from an immune perspective. 2014 , 182, 239-51	3
456	Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. 2014 , 36, 224-36	22
455	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. 2014 , 24, 743-50	440
454	Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4. 2014 , 5, 619	33
453	STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. 2014 , 6, 376-95	71
452	From bench to bedside: immunotherapy for prostate cancer. 2014 , 2014, 981434	17
451	Advances in Tumor Immunology and Immunotherapy. 2014 ,	0
450	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. 2014 , 14, 103-14	6
449	Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!. 2014 , 20, 5147-9	22
448	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. 2014 , 312, 1744-53	259
447	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. 2014 , 2, 31	68
446	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. 2014 , 5, 74	34
445	Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. 2014 , 2, 307-19	16
444	Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population. 2014 , 45, 325-30	15
443	Immunotherapy for solid tumors--a review for surgeons. 2014 , 187, 525-35	14

442	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. 2014 , 27, 89-97	90
441	CTLA4 blockade broadens the peripheral T-cell receptor repertoire. 2014 , 20, 2424-32	239
440	Interaction of Immune and Cancer Cells. 2014 ,	
439	Immune modulation in cancer with antibodies. 2014 , 65, 185-202	366
438	Recent developments in the medical and surgical treatment of melanoma. 2014 , 64, 171-85	46
437	Th1 cytokine-based immunotherapy for cancer. 2014 , 13, 482-94	43
436	Antibody-based immunotherapy for ovarian cancer: where are we at?. 2014 , 25, 322-31	32
435	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. 2014 , 287-313	
434	Immune modulation for cancer therapy. 2014 , 111, 2214-9	110
433	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. 2014 , 8, 1140-58	39
432	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. 2014 , 2, 17	58
431	Kidney injuries related to ipilimumab. 2014 , 32, 769-73	118
430	Therapeutic vaccines for cancer: an overview of clinical trials. 2014 , 11, 509-24	522
429	CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population. 2014 , 35, 6809-14	4
428	Tumor-Induced Immune Suppression. 2014 ,	1
427	Bevacizumab plus ipilimumab in patients with metastatic melanoma. 2014 , 2, 632-42	428
426	[Immunotherapy in epithelial ovarian carcinoma: hope and reality]. 2014 , 43, 198-210	1
425	Ipilimumab in patients with cancer and the management of dermatologic adverse events. 2014 , 71, 161-9	142

424	Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. 2014 , 2, 127-32	104
423	Promises and Challenges with Immunomodulatory Biologics. 2014 , 159-188	
422	Principles of Targeted Immunotherapy. 2015 , 27-38	
421	IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. 2015 , 5, 13650	13
420	Current evidence on the cytotoxic T-lymphocyte antigen 4 polymorphism and digestive system cancer risks: a meta-analysis involving 11,923 subjects. 2015 , 6, 105-8	1
419	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. 2015 , 13, 247	45
418	Immune checkpoint inhibitor therapy associated hypophysitis. 2015 , 8, 21-8	31
417	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. 2015 , 5, 202	154
416	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. 2015 , 2015, 191832	40
415	Monoclonal Antibodies for the Treatment of Cancer. 2015 , 683-694.e3	
414	Expressions of B7-H4 and B7-H3 Proteins and Effect of Sorafenib on their Expressions in Different Human Hepatoma Cell Lines. 2015 , 14, 1797	
413	The ipilimumab lesson in melanoma: achieving long-term survival. 2015 , 42, 387-401	23
412	Programmed death-1 checkpoint blockade in acute myeloid leukemia. 2015 , 15, 1191-203	50
411	Costimulation Immunotherapy in Infectious Diseases. 2015 , 83-129	3
410	Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials. 2015 , 359-373	
409	Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. 2015 , 33, 2947-53	17
408	Checkpoint inhibitors in immunotherapy of ovarian cancer. 2015 , 36, 33-9	16
407	[Breaking immune tolerance in cancer]. 2015 , 102, 34-52	2

406	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. 2015 , 34, 129-44	9
405	Targeted immune therapy of ovarian cancer. 2015 , 34, 53-74	23
404	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. 2015 , 34, 5411-7	39
403	Evolving Concepts: Immunity in Oncology from Targets to Treatments. 2015 , 2015, 847383	20
402	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. 2015 , 3, 1257-68	190
401	Evolving synergistic combinations of targeted immunotherapies to combat cancer. 2015 , 15, 457-72	447
400	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. 2015 , 709-738.e8	
399	Metastatic melanoma - a review of current and future treatment options. 2015 , 95, 516-24	153
398	Tumor infiltrating lymphocytes in ovarian cancer. 2015 , 16, 807-20	173
397	Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. 2015 , 37, 755-63	21
396	The role of checkpoints in the treatment of GBM. 2015 , 123, 413-23	12
395	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. 2015 , 123, 339-46	8
394	Immunotherapy for lung cancer: for whom the bell tolls?. 2015 , 36, 1411-22	14
393	Immunstimulation durch Checkpoint-inhibition. 2015 , 18, 31-34	
392	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. 2015 , 3, 11	214
391	Clinical deployment of antibodies for treatment of melanoma. 2015 , 67, 18-27	10
390	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. 2015 , 84, 1259-68	89
389	Targeting the immune system to treat lung cancer: rationale and clinical experience. 2015 , 9, 105-20	11

388	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. 2015 , 5, 151-69	18
387	Checkpoint blockade in combination with cancer vaccines. 2015 , 33, 7377-7385	31
386	Several immune escape patterns in non-Hodgkin's lymphomas. 2015 , 4, e1026530	62
385	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. 2015 , 17 Suppl 7, vii32-vii40	15
384	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. 2015 , 3, 1185-92	168
383	An overview of early investigational therapies for chemoresistant ovarian cancer. 2015 , 24, 1163-83	12
382	Integrating Immunotherapies in Prostate Cancer. 2015 , 17, 45	3
381	Immune Checkpoint Inhibitors. 2015 , 42, 55-66	93
380	Immunopharmacogenomics. 2015 ,	3
379	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2015 , 7, 1213-27	71
378	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. 2015 , 9, 1936-65	55
377	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. 2015 , 148, 132-53	43
376	Ovarian Cancer Therapeutic Opportunities. 2016 , 01,	
375	A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. 2016 , 7, 64390-64399	48
374	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. 2016 , 24, 7	3
373	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. 2016 , 7, 621	90
372	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. 2016 , 17,	41
371	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. 2016 , 8, 821-37	96

370	Overview and management of toxicities of immune checkpoint-blocking drugs. 2016 , 7, 28-37	1
369	Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice. 2016 , 39, 269-75	14
368	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. 2016 , 26, 469-80	25
367	Targeting T Cell Co-receptors for Cancer Therapy. 2016 , 44, 1069-78	314
366	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. 2016 , 16, 989-1004	9
365	Immune checkpoint inhibition in ovarian cancer. 2016 , 28, 339-48	96
364	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. 2016 , 5, e1151595	39
363	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. 2016 , 40, 466-473	22
362	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. 2016 , 12, 1247-53	32
361	Therapeutic targets and new directions for antibodies developed for ovarian cancer. 2016 , 8, 1437-1455	15
360	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146
359	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. 2016 , 107, 107-15	22
358	Developmental Therapeutics for Gynecologic Cancers: An Overview. 2016 , 99-125	
357	Gynecological Cancers. 2016 ,	
356	An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. 2016 , 7, 13443	122
355	Imaging Biomarkers in Immunotherapy. 2016 , 8, 1-13	24
354	Recent results of immunotherapy and perspectives for advanced NSCLC. 2016 , 5, 57-60	
353	Investigation of Cytotoxic T-lymphocyte antigen 4 Polymorphisms in Gastric Cardia Adenocarcinoma. 2016 , 83, 212-8	25

352	High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. 2016 , 5, e1128612	13
351	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. 2016 , 10, 395-401	184
350	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. 2016 , 5, 1136045	18
349	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. 2016 , 130, 25-74	119
348	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses. 2016 , 44, 274-86	94
347	Targeting the tumour microenvironment in ovarian cancer. 2016 , 56, 131-143	69
346	Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. 2016 , 226, 148-67	33
345	The Role of the Immune System in Ovarian Cancer and Implications on Therapy. 2016 , 12, 681-95	5
344	Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. 2016 , 5, e1090075	34
343	Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. 2016 , 61, 2132-9	16
342	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. 2016 , 6, 50-58	86
341	Advances in Therapeutic Cancer Vaccines. 2016 , 130, 191-249	71
340	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. 2016 , 27, 214-24	67
339	The role of microenvironment and immunity in drug response in leukemia. 2016 , 1863, 414-426	51
338	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. 2016 , 1865, 58-71	43
337	The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. 2017 , 451, 53-65	58
336	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. 2017 , 39, 327-331	16
335	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. 2017 , 20, 205-215	52

334	Vaccines and Immunostimulants. 2017 , 1-22	0
333	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. 2017 , 145, 420-425	42
332	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. 2017 , 5, 446-454	39
331	The swinging pendulum of cancer immunotherapy personalization. 2017 , 14, 259-270	3
330	Immunobiology and Immune Based Therapies of Melanoma. 2017 , 871-890	
329	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. 2017 , 9, 431-439	51
328	Recent progress in GM-CSF-based cancer immunotherapy. 2017 , 9, 347-360	103
327	Immune checkpoint inhibitors in renal cell carcinoma. 2017 , 131, 2627-2642	38
326	Mass Cytometry and Topological Data Analysis Reveal Immune Parameters Associated with Complications after Allogeneic Stem Cell Transplantation. 2017 , 20, 2238-2250	42
325	Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. 2017 , 24, T261-T281	30
324	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. 2017 , 28, 2377-2385	372
323	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. 2017 , 14, 611-620	4
322	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2
321	Ovarian Cancers. 2017 ,	1
320	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756	
319	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. 2017 , 13, 625-636	21
318	Immune Checkpoint Blockade in Breast Cancer Therapy. 2017 , 1026, 383-402	22
317	Silencing of suppressor of cytokine signaling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment. 2018 , 15, 1630-1638	1

316	Improving Outcomes through Immune System Modulation in the Treatment of Gynecological Malignancies. 2017 , 02,	
315	Targeting immune checkpoints in malignant glioma. 2017 , 8, 7157-7174	36
314	Update on immune checkpoint inhibitors in gynecological cancers. 2017 , 28, e20	45
313	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
312	Tipping Tumor Microenvironment against Drug Resistance. 2017 , 01,	2
311	The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer. 2017 , 08,	
310	Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. 2017 , 9,	5
309	Immune checkpoints, their control by immunotherapy and ovarian cancer. 2017 , 21, 189-196	2
308	Management of intracranial melanomas in the era of precision medicine. 2017 , 8, 89326-89347	12
307	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. 2017 , 8, 41641-41669	13
306	Immunotherapy in Gynecologic Cancers. 2017 ,	
305	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. 2018 , 20, 24	23
304	Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. 2018 , 7, e1444412	7
303	Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity. 2018 , 24, 3560-3571	45
302	Functions of NKG2D in CD8 T cells: an opportunity for immunotherapy. 2018 , 15, 470-479	47
301	Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. 2018 , 20, 28	8
300	Strategies to Reduce Intratumoral Regulatory T Cells. 2018 , 483-506	1
299	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. 2018 , 26, 420-434	79

298	Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. 2018 , 143-152	
297	Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. 2018 , 12, 48	22
296	Cancer immunotherapy using checkpoint blockade. 2018 , 359, 1350-1355	2480
295	Immune signatures predicting responses to immunomodulatory antibody therapy. 2018 , 51, 91-96	5
294	Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. 2018 , 28, 171-184	13
293	Towards personalized, tumour-specific, therapeutic vaccines for cancer. 2018 , 18, 168-182	453
292	CTLA-4: a moving target in immunotherapy. 2018 , 131, 58-67	356
291	Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. 2018 , 10, 392-399	9
290	Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies. 2018 ,	1
289	Immunological targets for cancer therapy: new recognition. 2018 , 7, 83-85	1
288	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. 2018 , 7, e1502905	50
287	Novel Systemic Treatments in High Grade Ovarian Cancer. 2018 ,	
286	Immunopharmacogenomics in Cancer Management. 2018 ,	
285	[Immunotherapy - The New Era of Oncology]. 2018 , 97, S3-S47	
284	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. 2018 , 29, 1727-1740	12
283	Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells. 2018 , 109, 2109-2118	13
282	Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients. 2018 , 19, 899-905	6
281	The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. 2018 , 10,	58

280	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. 2018 , 8, 86	529
279	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. 2018 , 7,	8
278	Immune checkpoint receptors: homeostatic regulators of immunity. 2018 , 12, 223-236	31
277	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. 2018 , 11, 104	164
276	Immunotoxicology of Biopharmaceuticals. 2018 , 826-851	
275	Complex interplay between tumor microenvironment and cancer therapy. 2018 , 12, 426-439	17
274	tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects. 2018 , 11, 4609-4619	17
273	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. 2019 , 74, 49-60	16
272	Melanoma Immunology and Immunotherapy. 2019 , 651-665	
271	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. 2019 , 7, 216	39
270	Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. 2019 , 9, 10742	6
269	Monoclonal Antibodies in Dermatocology-State of the Art and Future Perspectives. 2019 , 11,	6
268	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. 2019 , 42, 101295	8
267	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. 2019 , 36, 471-482	139
266	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. 2019 , 7,	20
265	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. 2019 , 10, 1782	23
264	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. 2019 , 20,	24
263	Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. 2019 , 9, 1015	28

262	Cardiotoxicity from immune checkpoint inhibitors. 2019 , 25, 100420	40
261	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. 2019 , 20,	28
260	The promising role of monoclonal antibodies for gastric cancer treatment. 2019 , 11, 347-364	7
259	Immune therapy of melanoma: Overview of therapeutic vaccines. 2019 , 234, 14612	18
258	New principles of cancer therapy give new hope for oncological patients. 2019 , 120, 15-18	2
257	The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. 2019 , 10, 911	57
256	Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients. 2019 , 10, 1079	4
255	The 100 top-cited studies in cancer immunotherapy. 2019 , 47, 2282-2292	16
254	Development of immune checkpoint therapy for cancer. 2019 , 216, 1244-1254	81
253	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. 2019 , 72, 100761	18
252	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. 2019 , 11,	22
251	GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. 2019 , 50, 796-811	117
250	Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway. 2019 , 145, 1921-1934	8
249	Clinical development of targeted and immune based anti-cancer therapies. 2019 , 38, 156	93
248	Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges. 2019 , 213-246	1
247	The Intersection between Tumor Angiogenesis and Immune Suppression. 2019 , 25, 5449-5457	120
246	Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. 2019 , 10, 467	77
245	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. 2019 , 17, 2583-2591	14

244	New development of Immune checkpoints blockade in cancer immunotherapy. 2019 , 131, 01022	1
243	Natural Products and Synthetic Analogs as a Source of Antitumor Drugs. 2019 , 9,	63
242	The past, present, and future of costimulation blockade in organ transplantation. 2019 , 24, 391-401	17
241	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. 2019 , 11, 161	21
240	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. 2019 , 46, 105-115	11
239	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. 2019 , 290, 9-22	95
238	Cancer immunotherapy: challenges and clinical applications. 2019 , 56, 1-3	15
237	Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. 2019 , 40, 225-233	4
236	The kaleidoscope of autoimmunity - From genes to microbiome. 2019 , 199, 1-4	7
235	Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. 2019 , 144, 2811-2822	22
234	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. 2019 , 29, 721-732	8
233	Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. 2020 , 1461, 73-103	11
232	Therapeutic Antibodies and Immunologic Conjugates. 2020 , 486-499.e8	1
231	Advances of functional nanomaterials for cancer immunotherapeutic applications. 2020 , 12, e1574	6
230	CMIP is a negative regulator of T cell signaling. 2020 , 17, 1026-1041	6
229	Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. 2020 , 76, 531-539	53
228	. 2020 ,	4
227	Microfluidics for Immuno-oncology. 2020 , 149-176	1

226	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. 2020 , 283-312	
225	Antibody and antibody fragments for cancer immunotherapy. 2020 , 328, 395-406	17
224	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. 2020 , 8,	6
223	Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. 2020 , 11, 964	24
222	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. 2020 , 8, 758	39
221	Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human V α V β T Cells. 2020 , 11, 1405	4
220	Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers. 2020 , 10,	6
219	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. 2020 , 11, 2023	12
218	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. 2020 , 21,	10
217	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. 2020 , 12,	8
216	Lynch Syndrome. 2020 ,	
215	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. 2020 , 83, 1130-1143	27
214	A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020 , 20, 651-668	746
213	Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient. 2020 , 17, 684-692	6
212	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. 2020 , 29, e13268	4
211	Cancer immunotherapy: dawn of the death of cancer?. 2020 , 1-18	1
210	Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer. 2020 , 11, 1152	2
209	The recent progress and therapy in endometriosis-associated ovarian cancer. 2020 , 83, 227-232	15

208	Biologically Responsive Plasmonic Assemblies for Second Near-Infrared Window Photoacoustic Imaging-Guided Concurrent Chemo-Immunotherapy. 2020 , 14, 3991-4006	50
207	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. 2020 , 40, 28-41	20
206	Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. 2020 , 13, 6109-6129	25
205	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. 2020 , 12,	20
204	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. 2020 , 52, 1-14	7
203	Reverting Immune Suppression to Enhance Cancer Immunotherapy. 2019 , 9, 1554	22
202	Prospects of biological and synthetic pharmacotherapies for glioblastoma. 2020 , 20, 305-317	9
201	Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. 2020 , 40, 19-27	9
200	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. 2020 , 10, 324	37
199	Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. 2021 , 66, 2129-2134	9
198	Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. 2021 , 66, 1974-1980	1
197	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. 2021 , 157, 103160	11
196	Varied functions of immune checkpoints during cancer metastasis. 2021 , 70, 569-588	6
195	Investigation of a new oxazolidine derivative in human resistance acute leukemia cells: deciphering its mechanism of action by label-free proteomic. 2021 , 394, 1153-1166	
194	Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. 2021 , 31-47	
193	Immune System Efficiency in Cancer and the Microbiota Influence. 2021 , 88, 170-186	5
192	NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer. 2021 , 17, 1995-2008	3
191	Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. 2021 , 156, 214-228	4

190	Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies. 2021 , 21, 404-425	2
189	Soluble forms of immune checkpoints in ovarian cancer. 2021 , 66, 80-86	
188	Green Propolis Compounds (Baccarin and p-Coumaric Acid) Show Beneficial Effects in Mice for Melanoma Induced by B16f10. 2021 , 8,	3
187	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. 2021 , 11, 1083-1097	7
186	Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. 2021 , 11, 648139	6
185	Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist. 2022 , 46, e15-e26	0
184	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. 2021 , 11, 631037	1
183	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. 2021 , 81, 971-984	2
182	Not-so-opposite ends of the spectrum: CD8 T cell dysfunction across chronic infection, cancer and autoimmunity. 2021 , 22, 809-819	20
181	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. 2021 , 9,	2
180	Senescence and Aging: Does It Impact Cancer Immunotherapies?. 2021 , 10,	1
179	Whole tumor cell vaccines engineered to secrete GM-CSF (GVAX). 2021 , 1, e1025	0
178	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. 2021 , 126, 630-638	6
177	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). 2021 , 9,	2
176	Spared Nerve Injury Causes Sexually Dimorphic Mechanical Allodynia and Differential Gene Expression in Spinal Cords and Dorsal Root Ganglia in Rats. 2021 , 58, 5396-5419	4
175	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. 2021 , 10,	1
174	Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives. 2021 , 22, 410-430	6
173	Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-Eatenin-driven M2 macrophage. 2021 , 23, 138-150	2

172	Checkpoint blockade: the end of the beginning. 2021 , 21, 621	0
171	Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes. 2021 , 96, 13-18	2
170	Immune checkpoint blockade therapy in high-grade glioma. 2022 , 91-108	
169	Bispecific antibodies: A promising entrant in cancer immunotherapy. 2021 , 233-266	
168	Cancer as a chronic inflammatory disease: role of immunotherapy. 2004 , 21-51	3
167	Ipilimumab. 2016 , 275-296	1
166	Antibody Therapies in Cancer. 2016 , 909, 1-67	7
165	Immunotherapy for Lynch Syndrome Patients. 2020 , 117-122	1
164	Antibodies and Fusion Proteins. 2008 , 309-332	1
163	Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. 2017 , 13, 907-919	8
162	Immunotherapy transforms cancer treatment. 2019 , 129, 46-47	21
161	SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. 2006 , 116, 90-100	138
160	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. 2006 , 116, 1935-45	531
159	MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. 2007 , 117, 1902-13	158
158	Harnessing the immune system to treat cancer. 2007 , 117, 1130-6	88
157	CD200 is induced by ERK and is a potential therapeutic target in melanoma. 2007 , 117, 3922-9	76
156	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. 2015 , 125, 3377-83	108
155	Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. 2009 , 4, e6094	17

154	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. 2013 , 8, e53745	343
153	B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis. 2017 , 8, 68825-68836	3
152	Investigation of polymorphisms in non-small cell lung cancer: a case-control study. 2017 , 8, 76634-76643	6
151	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. 2020 , 27, 2402-2448	6
150	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. 2017 , 18, 315-331	32
149	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. 2019 , 39, 781-790	15
148	Immunotherapeutic strategies: the melanoma example. 2009 , 1, 679-90	9
147	Colitis associated with biological agents. 2012 , 18, 1871-4	58
146	[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. 2019 , 22, 369-379	2
145	Targeted therapy of ovarian cancer including immune check point inhibitor. 2017 , 32, 798-804	30
144	Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis. 2013 , 25, 671-8	9
143	Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. 2019 , 26, 221	2
142	Immune Checkpoint Blockers and Ovarian Cancer. 2017 , 38, 182-189	3
141	Immune checkpoint inhibitors: Advances and impact in neuro-oncology. 2019 , 10, 9	13
140	Current evidence on associations between the MMP-7 (-181A>G) polymorphism and digestive system cancer risk. 2013 , 14, 2269-72	15
139	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. 2021 , 184, 5309-5337	70
138	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. 2021 , 11, 737497	1
137	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. 2021 , 8, 756870	0

136 Tumor Vaccines for Breast Cancer. **2007**, 297-312

135 Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?. **2008**, 293-306

134 Regulatory T Cells and Tumour Immunotherapy. **2008**, 379-392

133 New Approaches for Optimizing Melanoma Vaccines. **2008**, 143-160

132 Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. **2009**, 575-590

131 Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention. **2009**, 263-279

130 Monoclonal Antibody Therapy for Hematologic Malignancies. **2010**, 493-536

129 Malignant Melanoma. **2010**, 621-632

128 Immunotoxicology of Biopharmaceutics. **2010**, 489-519

127 Ovarian Cancer Immunology and Immunotherapy. **2011**, 203-221

126 The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. **2011**, 211-228

1

125 L  batacept dans la polyarthrite rhumato  de. **2011**, 77-90

124 Immuuntherapie van kanker. **2011**, 211-217

123 Targeting regulatory T cells and other strategies to enable cancer vaccines. **2011**, 182-201

122 Myeloablative Transplant (HCT). **2012**, 169-186

121 Basic Principles of Immunology in Urology. **2012**, 495-529.e5

120 Tumorthherapie. **2013**, 422-433

119 Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. **2014**, 233-258

- 118 T Cell Co-regulatory Signals and Their Role in Cancer Therapy. **2014**, 323-341
- 117 What Is the Future of Immunotherapy in Ovarian Cancer?. **2014**, 323-337
- 116 Novel insights/translational implication from the emerging biology of melanoma. **2014**, 1102, 3-9 2
- 115 Melanom. **2014**, 31-97
- 114 Monoclonal Antibodies. 241-247
- 113 Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. **2014**, 435-462
- 112 Immunotoxicology of Biopharmaceutics?. **2014**,
- 111 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2015**, 87-129
- 110 Frontiers in Cancer Immunotherapy. **2015**, 1-22
- 109 Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. **2015**, 85-101
- 108 Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. **2016**, 7, 4-16
- 107 The Future in Ovarian Cancer: Advances in Immunotherapies. **2017**, 143-168
- 106 Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases. **2017**, 4, 395-412 5
- 105 Introduction to Melanoma Immunology. **2019**, 1-15
- 104 Melanoma Immunology and Immunotherapy. **2019**, 1-15
- 103 Melanom. **2019**, 45-134
- 102 The development trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics.
- 101 Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. **2021**, 2021, 9453692

- 100 Technological Advances in Accelerated Wound Repair and Regeneration. **2020**, 12, 717-737
- 99 Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. **2021**, 21, 162-186 ○
- 98 Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm. **2021**, 21-30
- 97 Introduction to cancer and treatment approaches. **2022**, 1-27 1
- 96 Response Evaluations for Precision Cancer Therapy and Immunotherapy. **2020**, 15-27
- 95 Cancer immunotherapy. **2020**, 55, 61-66
- 94 Tumor Immunology and Cancer Vaccines. **2005**, 293-336
- 93 CD137/CD137 Ligand in Tumor and Viral Immunotherapy. **2006**, 117-135
- 92 Regulatory T Cells in Cancer. **2008**, 41-67
- 91 Dendritic Cell Vaccines. **2007**, 251-274
- 90 Adoptive Cellular Therapy for the Treatment of Cancer. **2007**, 343-361
- 89 Checkpoint Blockade and Combinatorial Immunotherapies. **2007**, 363-390
- 88 T Cells and Antigen Recognition. **2007**, 33-53
- 87 Immunomodulatory Molecules of the Immune System. **2007**, 67-121
- 86 DNA Vaccines Against Cancer. **2007**, 193-215
- 85 Major properties of dendritic cells and their actual and potential applications in cancer therapy and infectious disease prophylaxis. **2008**, 111-159
- 84 Drug Development in Cancer Medicine: Challenges for Targeted Approaches. **2008**, 383-410
- 83 Targeted Therapy in Melanoma. **2008**, 183-211

82	Novel Therapies for Renal Cell Cancer. 2007 , 161-186	
81	Immunobiology and Immune-Based Therapies of Melanoma. 2008 , 245-262	
80	Frontiers in Cancer Immunotherapy. 2021 , 1-23	
79	Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials. 2021 , 349-364	
78	A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. 2008 , 6, 955-964	123
77	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. 2009 , 9, 3	125
76	Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. 2008 , 8, 9	21
75	GM-CSF-secreting vaccines for solid tumors: moving forward. 2010 , 10, 52-60	40
74	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. 2011 , 84, 381-9	32
73	The enduring tale of T cells in HIV immunopathogenesis. 2013 , 138, 682-99	6
72	T cell coinhibition and immunotherapy in human breast cancer. 2012 , 14, 229-36	27
71	Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population. 2015 , 8, 11519-23	1
70	Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. 2019 , 12, 123-132	4
69	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. 2021 , 13,	0
68	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. 2021 , 40, 102492	0
67	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. 2021 , 1342, 273-295	1
66	The emerging role of Arid5a in cancer: A new target for tumors. 2022 ,	
65	PARP mediated DNA damage response, genomic stability and immune responses.. 2021 ,	3

64	Recent Advances in the Role of Arid5a in Immune Diseases and Cancer.. 2021 , 12, 827611	0
63	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.. 2022 , 12,	0
62	Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma. 2021 , 14, 1038-1047	
61	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.. 2022 , 22, e2	8
60	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.. 2022 , 113, 295-350	1
59	Recent developments in cancer vaccines. 2022 , 29-75	
58	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis.. 2022 , 3, 100526	0
57	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.. 2022 , 15, 24	8
56	Strategies for Manipulating T Cells in Cancer Immunotherapy.. 2022 ,	
55	Research trends of immune checkpoint blockade in melanoma: a visualization and bibliometric analysis (Preprint).	0
54	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.. 2021 , 23,	1
53	The foundations of immune checkpoint blockade and the ipilimumab approval decennial.. 2021 ,	15
52	Immunotherapy Resistance in Glioblastoma.. 2021 , 12, 750675	1
51	Cardiac complications of cancer therapies. 2022 ,	0
50	A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima [®] in Chinese healthy subjects.. 2022 , 1-10	
49	Presentation_1.pdf. 2020 ,	
48	Image_1.TIF. 2019 ,	
47	Image_10.TIF. 2019 ,	

46 Image_11.TIF. **2019**,

45 Image_12.TIF. **2019**,

44 Image_13.TIF. **2019**,

43 Image_14.TIF. **2019**,

42 Image_2.TIF. **2019**,

41 Image_3.TIF. **2019**,

40 Image_4.TIF. **2019**,

39 Image_5.TIF. **2019**,

38 Image_6.TIF. **2019**,

37 Image_7.TIF. **2019**,

36 Image_8.TIF. **2019**,

35 Image_9.tif. **2019**,

34 Table_1.pdf. **2020**,

33 Image_1.TIF. **2019**,

32 The interplay of immunotherapy, chemotherapy, and targeted therapy in trippe negative breast cancer (TNBC). **2022**, 149-176

31 Development of Cancer Immunotherapies.. **2022**, 183, 1-48

30 The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.. **2022**,

29 Glycans as shapers of tumor microenvironment: a sweet driver of T cell-mediated anti-tumor immune response.. **2022**,

28	Double Trouble: Immunotherapy Doublets in Melanoma Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. 2022 , 1-22	0
27	PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo. 2022 , 14, 3095	2
26	Modelling the tumor immune microenvironment for precision immunotherapy. 2022 , 11,	1
25	The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling. 2022 , 14, 3164	2
24	Ovarialkarzinom: Immuntherapie, quo vadis?.	
23	Immune Checkpoint Inhibitors in Cancer Therapy How to Overcome Drug Resistance?. 2022 , 14, 3575	2
22	Chokeberry (Aronia melanocarpa) fruit extract abrogates melanoma progression through boosting up IFN- γ -producing cells. 2022 , 95, 105185	
21	Investigation of CTLA4 Application in Advanced Melanoma with Ipilimumab and Nivolumab. 8, 481-489	
20	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. 2005 , 11, 129-138	7
19	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
18	In Silico Inhibition of Three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal Immunoablative Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough..	0
17	In Silico Inhibition of three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal Immunoablative Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough..	0
16	Imaging of Drug-Related Pneumonitis in Oncology.	0
15	Systemic benefit of radiation therapy via abscopal effect. 12,	0
14	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. 2022 , 113, 109300	0
13	Immunotherapy in gynecologic malignancies. 2023 , 506-520.e7	0
12	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer.	0
11	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. 2023 , 23,	0

- 10 Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. **2023**, 12, 258
- 9 New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. **2023**, 24, 4044
- 8 The role of LncRNAs in tumor immunotherapy. **2023**, 23,
- 7 Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity. **2023**, 26, 106288
- 6 Diversity of immune checkpoints in cancer immunotherapy. 14,
- 5 Novel technologies for applying immune checkpoint blockers. **2023**,
- 4 Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. **2023**, 59,
- 3 Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T Cells. **2023**, 28, 3311
- 2 Biomimetic and bioinspired nano-platforms for cancer vaccine development.
- 1 Research Hotspot and Application Status of Immune Evasion Mechanism in Ovarian Cancer. **2023**, 11, 443-455